Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X2EM
|
|||
| Former ID |
DIB013621
|
|||
| Drug Name |
UNI-PH (1-34)
|
|||
| Synonyms |
Recombinant parathyroid hormone 1-34 (osteoporosis), Uni-Bio Science Group; RhPTH 1-34 (osteoporosis), Uni-Bio Science Group
Click to Show/Hide
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Phase 2 | [1] | |
| Company |
Uni-Bio Science Group Limited
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Parathyroid hormone receptor (PTH2R) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Class B/2 (Secretin family receptors) | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH in postmenopausal women with osteoporosis. Clin Pharmacokinet. 2013 Nov;52(11):995-1004. | |||
| REF 2 | Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ. 2006 July 4; 175(1): 52-59. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.